This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Raptor Pharmaceutical Obtains Tissue Fibrotic Disease Intellectual Property Related To Cysteamine

Stocks in this article: RPTP

NOVATO, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that the Company has acquired exclusive world-wide rights to intellectual property related to cysteamine and related compounds in the potential treatment of tissue fibrosis from the Seattle Children's Research Institute ("SCRI").

Raptor's agreement with SCRI provides exclusive rights to technology related to compositions and methods for treating patients having or being at risk of developing pathological fibrosis including chronic kidney disease ("CKD"). Raptor holds a portfolio of intellectual property related to composition of matter and methods of use of cysteamine and related compounds, covering therapeutic applications, including genetic diseases, metabolic disorders and neurological diseases. Raptor's RP103, its proprietary, delayed-release oral formulation of cysteamine bitartrate, is in clinical development for the potential treatment of nephropathic cystinosis, a rare metabolic lysosomal storage disease, Huntington's Disease, a genetic neurological disease, and non-alcoholic steatohepatitis ("NASH"), a severe form of non-alcoholic fatty liver disease.

In addition to other fibrotic conditions, the license covers the use of cysteamine or cystamine in the potential amelioration of progressive interstitial renal fibrosis by modulating oxidative stress. Researchers at SCRI have shown in preclinical studies in mice that daily treatment with cysteamine attenuated renal fibrosis, with up to 25% reduction of extracellular fibrotic material observed over a 21-day study period.

"Fibrosis can occur in many organ systems in the body resulting in serious health and in some cases life-threatening consequences," said Patrice P. Rioux, M.D., Ph.D., Raptor's Chief Medical Officer. "This licensing agreement with Seattle Children's Research Institute further expands the applications of our cysteamine formulations in the potential treatment of fibrotic disease, including chronic kidney, liver and severe gastrointestinal diseases, as well as metabolic diseases, and we look forward to continuing to collaborate with the SCRI researchers as we expand our clinical development into these areas."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs